Compare Supplements

Side-by-side comparison of 1 supplements

Pet3.2

Petrelintide

Limited safety

Evidence

Evidence Score3.2/10

Studies: 5

Meta-analyses: 0

Dosage & timing

Dosage:

Investigational — NO approved dose. Phase-1 trials used single subcutaneous doses of 0.04-2.4 mg and once-weekly subcutaneous dosing escalated every two weeks to target doses of 2.4, 4.8, and 9.0 mg. There is no approved or established regimen; do not self-dose an unapproved drug.

Best Time:

Any time

Can take on empty stomach

Form:

Once-weekly subcutaneous injection (investigational only)

What you'll notice

⚖️ Early weight loss (phase-1 only)positive

Up to 16 weeks (phase-1)

🩺 Good early tolerabilitypositive

Phase-1 trials

🤢 Gastrointestinal adverse eventstrade-off

Especially during up-titration

Safety

Limited safety

Contraindications:

Not a dietary supplement and not an approved drug — investigational; do not self-source grey-market vials
History of pancreatitis (amylin/incretin-class caution)
Pregnancy and breastfeeding

Drug Interactions:

Oral medications (delayed gastric emptying)
Insulin / insulin secretagogues (sulfonylureas)
GLP-1 / incretin drugs (e.g. semaglutide)

Side Effects:

NauseaOther GI effects (diarrhoea, vomiting)Injection-site reactions

Want to compare more supplements?

Loading comparison...